AC2993 LAR
Goal of once-a-month administration of AC2993
- Targeting treatment of type 2 diabetes
Utilizes Alkermes’ FDA approved Medisorb® technology
- Biodegradable polymer matrix
Phase 1 study initiated in March 2001
- Results expected in 3Q 2001
Target Phase 2 initiation 2H 2001 pending positive Phase 1 results